Non-alcoholic steatohepatitis (NASH) is a chronic fatty liver disease driven by a complex network of molecules called cyclophilins. Cyclophilins A, B, and D regulate disease processes such as mitochondrial damage, inflammation, and fibrosis of liver cells.
Hepion Pharmaceutical’s lead oral drug candidate, CRV431, targets all three cyclophilins by blocking their attachment to cell receptors. The goal of this animation is to educate their patients about the science and versatility of their drug.
Visit our process page to see how our award winning animations get created.
1275 Shiloh Road, Suite 3130 Kennesaw, GA 30144 | Toll-free: 800-333-0753 | Phone: 770-805-0460 | Email: Nucleus Medical Media
©2021 Nucleus Medical Media. All rights reserved.